logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Kevin Beaumont

This inventor holds 8 USPTO granted patents and 1 EPO patent. Top assignee: Amylin Pharmaceuticals, Inc.. Active years: 1993-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin Beaumont. Retrieved from https://idiyas.com/inventor/kevin-beaumont

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 8

% Patents Active = 75.0


Average Co-Inventor Count = 2.5

ph-index = 6

Forward Citations = 135(Granted Patents)


Company Filing History:

goldMedal8 out of 164 
 
Amylin Pharmaceuticals, Inc.
 patents

Years Active: 1993-2005

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents
1. 6936584 - Mixed amylin activity compounds (2005-08-30),
2. 6602694 - Uncoupling protein 4 (UCP-4) (2003-08-05),
3. 5625032 - Selective amylin antagonist peptides and uses therefor (1997-04-29),
4. 5580953 - Amylin antagonist peptides and uses therefor (1996-12-03),
5. 5527771 - Methods and Compositions for treatment of diabetes mellitus, (1996-06-18),
6. 5508260 - Methods and compositions for treatment of diabetes mellitus, (1996-04-16),
7. 5321008 - Methods and compositions for treatment of diabetes mellitus, (1994-06-14),
8. 5264372 - Receptor-based screening methods for amylin agonists and antagonists (1993-11-23),

Sure! Here is the article about inventor Kevin Beaumont:

Title:

Kevin Beaumont: A Pioneer in Innovation

Introduction:

Kevin Beaumont, a man with a relentless drive for innovation, is reshaping the world of inventions with his groundbreaking ideas and patents. Hailing from San Diego, CA (US), Beaumont's passion for pushing the boundaries of what is possible makes him a true pioneer in the field.

Latest Patents:

1. Mixed Amylin Activity Compounds: Beaumont's patented compounds inhibit certain activities of amylin while acting as amylin agonists in other aspects. These innovative compounds are revolutionizing the treatment of disturbances in fuel metabolism, including diabetes mellitus, impaired glucose tolerance, and insulin resistance.

2. Uncoupling Protein 4 (UCP-4): Beaumont's discovery of the novel uncoupling protein, UCP-4, holds great promise in regulating thermogenesis and respiratory ATP synthesis. This patent has far-reaching implications in treating conditions such as obesity, diabetes, malignant hyperthermia, and fever.

Career Highlights:

Kevin Beaumont is a valued member of Amylin Pharmaceuticals, Inc., where his inventive spirit fuels the company's success. With a total of 8 patents to his name, Beaumont's contributions have left an indelible mark on the pharmaceutical industry, particularly in the fields of diabetes management and metabolic disorders.

Collaborations:

Beaumont's collaborative efforts with coworkers like Andrew A Young and Kathryn Susan Prickett have led to the successful development and implementation of innovative solutions in the medical field. Their teamwork has not only driven scientific progress but has also inspired the next generation of inventors to think creatively and shape a better future.

Conclusion:

Inventor Kevin Beaumont's dedication to innovation and commitment to excellence continue to inspire those around him. His groundbreaking patents and pioneering work in the field of medicine highlight his unwavering passion for creating a better world through inventions. Beaumont stands as a shining example of how one individual's drive and creativity can have a lasting impact on society.

Is there anything else you would like to know about Kevin Beaumont or any other inventor?

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…